Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

PURPOSE: Dual human epidermal growth factor receptor 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free survival in metastatic disease. CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and lapat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Carey, Lisa A., Berry, Donald A., Cirrincione, Constance T., Barry, William T., Pitcher, Brandelyn N., Harris, Lyndsay N., Ollila, David W., Krop, Ian E., Henry, Norah Lynn, Weckstein, Douglas J., Anders, Carey K., Singh, Baljit, Hoadley, Katherine A., Iglesia, Michael, Cheang, Maggie Chon U., Perou, Charles M., Winer, Eric P., Hudis, Clifford A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2016
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4980567/
https://ncbi.nlm.nih.gov/pubmed/26527775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.1268
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller